sorafenib has been researched along with mdv 3100 in 4 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (mdv 3100) | Trials (mdv 3100) | Recent Studies (post-2010) (mdv 3100) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 1,546 | 182 | 1,502 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 2 (50.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Bian, J; Cheng, Y; Duan, J; Gao, X; Wu, H; Yang, Y; You, L; Zhang, L; Zhang, X; Zhu, Q | 1 |
Abou-Alfa, GK; Boussayoud, C; Capanu, M; Chou, JF; Do, GK; El Dika, I; Ferrer, CS; Harding, JJ; Iyer, R; Kelley, RK; Khalil, DN; Kuhn, P; Muenkel, K; Rodriguez-Lee, M; Ruiz, C; Shia, J; Tan, B; Wilton, J; Yarmohammadi, H | 1 |
Daniele, B; Lim, HY; López, B; Palmer, DH; Park, SR; Rimassa, L; Ryoo, BY; Steinberg, J | 1 |
2 trial(s) available for sorafenib and mdv 3100
Article | Year |
---|---|
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
Topics: Benzamides; Carcinoma, Hepatocellular; Double-Blind Method; Humans; Liver Neoplasms; Nitriles; Phenylthiohydantoin; Sorafenib | 2021 |
2 other study(ies) available for sorafenib and mdv 3100
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Receptors, Androgen; Signal Transduction; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |